Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Marlotamig · REGN-7075

Bispecific antibody · Immune activation, directed at Epidermal growth factor receptor (EGFR) and CD28 · developed by REGENERON PHARMACEUTICALS

Phase 2 Most advanced trial
REGN Developer

What is Marlotamig?

Marlotamig is a bispecific antibody that binds both CD28 on cytotoxic T-lymphocytes and epidermal growth factor receptor (EGFR) on tumor cells. By engaging both, it redirects and activates T cells against EGFR-expressing cells. It is being studied in non-small cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
REGN-7075
Drug type
Bispecific antibody
Targets
Epidermal growth factor receptor (EGFR), CD28
Mechanism
Immune activation, directed at Epidermal growth factor receptor (EGFR) and CD28
Pathways
T-cell activation, CTL-mediated tumor cell killing
Therapy area
Oncology
Developer
REGENERON PHARMACEUTICALS (REGN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
02Z59O1UOM

Conditions studied

Non Small Cell Lung CancerNSCLC

Other drugs acting on EGFR / CD28

More from REGENERON PHARMACEUTICALS

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the REGN page.

Follow REGN, the company behind Marlotamig

See REGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

REGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.